{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:41Z","timestamp":1761895421935},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.critrevonc.2012.01.001","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T13:32:44Z","timestamp":1327930364000},"page":"93-100","source":"Crossref","is-referenced-by-count":27,"title":["Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data"],"prefix":"10.1016","volume":"84","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2012.01.001_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0015","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1073\/pnas.0607006103","article-title":"The age incidence of chronic myeloid leukemia can be explained by a one-mutation model","volume":"103","author":"Michor","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/003693300404900305","article-title":"The Scotland Leukemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukemia in 1999 and 2000","volume":"49","author":"Harrison","year":"2004","journal-title":"Scott Med J"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0030","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.critrevonc.2010.06.001","article-title":"Targeted ant-cancer therapy in the elderly","volume":"78","author":"Gonsalves","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0040","first-page":"1233","article-title":"Old age is a sign of poor prognosis in patients with chronic myelogenous leukemia","volume":"80","author":"Kantarjian","year":"1988","journal-title":"Southern Med J"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(97)89522-8","article-title":"Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older","volume":"100","author":"Cortes","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(98)00064-2","article-title":"Interferon-alpha for the treatment of elderly patients with chronic myeloid leukemia","volume":"22","author":"Hilbe","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0055","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/sj.leu.2403042","article-title":"Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha","volume":"17","author":"Berger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.leukres.2005.03.001","article-title":"Elderly patients with Ph+ chronic myelogenous leukemia (CML): results off imatinib mesylate treatment","volume":"29","author":"Latagliata","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact off age on the outcome off patients with chronic myeloid leukemia in late chronic phase: results off a phase II study off the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"\u201cReal-life\u201d results of front-line treatment with imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0080","first-page":"253","article-title":"Therapy with imatinib in elderly CML patients (>65 years) is well tolerated but cytogenetic and molecular remissions seem to be achieved later compared to younger patients","volume":"94","author":"Pletsch","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0085","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.leukres.2011.01.017","article-title":"Evaluation of tolerability and efficacy on imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study","volume":"35","author":"Sanchez-Gujio","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0090","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment off chronic myeloid leukemia: no impact off age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0095","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0100","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood.V112.11.3233.3233","article-title":"Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis","volume":"112","author":"Lipton","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0105","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood.V114.22.3286.3286","article-title":"Efficacy and safety off nilotinib in elderly patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML) in chronic phase 8CP: a sub-analysis off the ENACT (Expanding nilotinib access in clinical trials) study","volume":"114","author":"le Coutre","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0110","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0115","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance\/intolerance to imatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3421.3421","article-title":"Safety and efficacy of dasatinib vs imatinib by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial","volume":"116","author":"Khoury","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.01.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3768.3768","article-title":"Nilotinib shows safety and efficacy in older patients (<65 years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd","author":"Larson","year":"2011","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T11:15:35Z","timestamp":1593602135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842812000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1040842812000029"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.01.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}